Reuters logo
BRIEF-Astrazeneca says US FDA approves expanded indication for brilinta
September 4, 2015 / 6:11 AM / 2 years ago

BRIEF-Astrazeneca says US FDA approves expanded indication for brilinta

Sept 4 (Reuters) - Astrazeneca Plc :

* Announces that US Food And Drug Administration (FDA) has approved brilinta  (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond first year

* US FDA approves expanded indication for brilinta

* New brilinta 60mg tablet is expected to be available in pharmacies by end of September 2015 Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below